EMJ Cardiology 6.1 2018

October 2018

Journal Info

Welcome

As well as capturing the event’s bustling atmosphere within the pages of its Congress Review, this year’s eJournal presents key research, discussion, and future directions for cardiological medicine.

View in Zmags

Click here to view EMJ Cardiology 6.1 2018 in Zmags.

Browse

EMJ Cardiology 6.1 2018

EMJ Cardiology 6.1 2018

Journal Info

Welcome

View in Zmags

Aims and scopes

Editorial expertise

Peer review

Submission and instructions to author

Reprints

Distribution and readership

Editorial board

Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor

Editor’s Pick: Contemporary Use of Intracoronary Imaging in Percutaneous Coronary Intervention

A Comparison of Different Doses of Dexmedetomidine for Myocardial Protection in Percutaneous Coronary Interventional Patients

Cardioprotective Approaches to the Management of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Do We Need Increased Surveillance in Elderly Women on Trastuzumab?

Therapeutic Area

Omnipresent

About Us

Browse

Login to continue

Members

Create Account

EMJ Cardiology 6.1 2018

EMJ Cardiology 6.1 2018

Journal Info

Welcome

View in Zmags

Aims and scopes

Editorial expertise

Peer review

Submission and instructions to author

Reprints

Distribution and readership

Editorial board

Latest articles

Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor

Editor’s Pick: Contemporary Use of Intracoronary Imaging in Percutaneous Coronary Intervention

A Comparison of Different Doses of Dexmedetomidine for Myocardial Protection in Percutaneous Coronary Interventional Patients

Cardioprotective Approaches to the Management of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Do We Need Increased Surveillance in Elderly Women on Trastuzumab?